Kestra Medical Technologies (NASDAQ:KMTS) Sets New 1-Year High - Time to Buy?

Key Points

• Kestra Medical Technologies reached a new 52-week high of $30.10, trading near $29.91, giving the company a market capitalization of approximately $1.79 billion.
• Analyst sentiment is moderately positive, with five Buy, two Hold, and one Sell rating; however, the average price target of $29.00 is below the stock’s recent trading level.
• The company reported a larger-than-expected quarterly loss of $0.75 per share, alongside deeply negative margins and return on equity. Insiders have also sold 361,928 shares worth about $9.2 million over the past three months.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $30.10 and last traded at $29.9050, with a volume of 91,399 shares. The stock had previously closed at $29.42.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Weiss Ratings raised shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 16th. BTIG Research reiterated a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Wall Street Zen lowered shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Royal Bank Of Canada set a $30.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.00.

Kestra Medical Technologies Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a fifty day moving average price of $26.51 and a 200 day moving average price of $23.73. The firm has a market capitalization of $1.79 billion, a PE ratio of -11.21 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). The business had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. Research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Insider Transactions at Kestra Medical Technologies

In other news, insider Traci Umberger sold 100,000 shares of Kestra Medical Technologies stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the transaction, the insider owned 195,825 shares in the company, valued at $5,322,523.50. The trade was a 33.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Webster sold 15,000 shares of the company's stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $29.56, for a total value of $443,400.00. Following the sale, the insider owned 445,215 shares in the company, valued at $13,160,555.40. The trade was a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 361,928 shares of company stock valued at $9,158,873. Corporate insiders own 5.30% of the company's stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC raised its holdings in Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after acquiring an additional 784 shares during the period. Quantinno Capital Management LP bought a new stake in Kestra Medical Technologies during the first quarter worth about $431,000. California State Teachers Retirement System grew its position in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock valued at $555,000 after purchasing an additional 7,844 shares during the last quarter. Spartan Wealth Advisory Services LLC bought a new stake in shares of Kestra Medical Technologies in the first quarter worth approximately $603,000. Finally, Bank of New York Mellon Corp grew its position in Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock valued at $1,397,000 after buying an additional 22,471 shares during the period.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.